STORY UPDATE
Continue reading below...
WebinarsAccelerating rare disease clinical trials
Explore how a rare kidney disease trial achieved faster patient enrollment with data-informed strategies and collaborative partnerships.
Read MoreLYONS, France—May 15, 2007—Animal model specialist genOway announced it successfully completed its initial public offering on Alternext to great interest, with demand outstripping supply 10-fold. The capital will provide resources for extending the company's R&D efforts through innovation and licensing.
WILMINGTON, Mass.—Charles River Laboratories announced recently the formation of a strategic alliance with Lyon, France-based genOway, a leader in genetically modified model organisms. The deal will see the two companies provide animal models of human disease to markets worldwide, combining the regional expertise of each partner. According to William Barbo, vice president of Research Model Services at Charles River, the North American company will promote genOway's solutions and further assist Charles River clients efficiently pursue their research goals.
Charles River is a market leader in model development, breeding services and model characterization, while genOway holds IP for a variety of research solutions including several knock-in and knock-out systems, as well as inducible-gene expression models.
"We are thrilled to begin this exciting new collaboration with Charles River promoting our wide array of proprietary solutions and services to the North American market," said Alexandre Fraichard, CEO of genOway. "Charles River, the acknowledged market leader in this segment, shares our commitment to unsurpassed customer service, and to offering clients what they truly want and need."
